ExpreS2ion Biotechnologies successfully launches its IPO at First North Stockholm
Copenhagen, August 8, 2016
ExpreS2ion Biotech Holding AB approved for listing on Nasdaq Stockholm First North. This entry was posted on July 27, 2016
ExpreS2ion Biotech Holding AB (“ExpreS2ion “) announces that the Company has met the requirements for listing on Nasdaq Stockholm First North and today, July 27, it has received the stock exhange’s formal approval. The first day of trading of ExpreS2ion’s shares is expected to be July 29, 2016.
CEO Clas Dyrholm comments: “In June we carried out a successful Initial Public Offering (IPO), which reflected the interest there is in ExpreS2ion. With the proceeds from the IPO, we can now continue to expand our marketing and sales efforts to enable a larger market penetration for our ExpreS2 platform.”